REGENXBIO Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
On track to dose first patient for Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia by the end of 2016 Initiated manufacturing of material for Phase I clinical trial of RGX-314 for the treatment of wet age- …